News | 30 July 2012
It's not just Lipitor and its copycats: all generic drugs bear the brunt of sharp price erosion, especially in the competitive American market. And Indian pharma companies, which get a significant share of their revenues from selling generic drugs to ...
Click on the link to read the full article at Outlook
(This link will open in a new window)